San Diego, California, United States
George Schreiner, Sundeep Dugar, Russell Cox
2017
Private company
Series A
85
The Longevity Fund, Arch Venture Partners, Adam Street Ventures, Longitude Ventures, Vertex Ventures, Bluebird Ventures
Mitochondrial dysfunction
Becker muscular dystrophy, Duchenne muscular dystrophy
small molecule drugs
Phase 1 Trials
EPM-01
We are a clinical stage biopharmaceutical company that has uncovered unique insights into the biology of mitochondrial biogenesis and function, leading to an advanced understanding of its clinical effect in disease. These findings have led to the discovery of a novel, previously undescribed pharmacological approach to the treatment of diseases characterized by deficits in these pathways. We have identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and function. We are currently developing our lead clinical candidate, which has been shown to trigger mitochondrial biogenesis in early human studies, as a potential treatment across a number of therapeutic areas, starting with rare diseases.